Evolution of resistance to thyroid cancer therapy.
Nucera, Carmelo. 2016. “Evolution of Resistance to Thyroid Cancer Therapy.”. Aging 8 (8): 1576-7.
Search
Search results
735 results found
Identification of insertions in PTEN and TP53 in anaplastic thyroid carcinoma with angiogenic brain metastasis.
Sadow, Peter M, Dora Dias-Santagata, Zongli Zheng, Derrick T Lin, Long Phi Le, and Carmelo Nucera. 2015. “Identification of Insertions in PTEN and TP53 in Anaplastic Thyroid Carcinoma With Angiogenic Brain Metastasis.”. Endocrine-Related Cancer 22 (6): L23-8.
Genomic and immunohistochemical analysis in human adrenal cortical neoplasia reveal beta-catenin mutations as potential prognostic biomarker.
Kovach, Alexandra E, Carmelo Nucera, Quynh T Lam, Ahnthu Nguyen, Dora Dias-Santagata, and Peter M Sadow. 2015. “Genomic and Immunohistochemical Analysis in Human Adrenal Cortical Neoplasia Reveal Beta-Catenin Mutations As Potential Prognostic Biomarker.”. Discoveries (Craiova, Romania) 3 (2).
Discoveries: an innovative platform for publishing cutting-edge research discoveries in medicine, biology and chemistry.
Bucur, Octavian, Alexandru Almasan, Barbara S Nikolajczyk, Garth L Nicolson, Jack Lawler, Victor E Velculescu, Sorin Draghici, et al. 2013. “Discoveries: an Innovative Platform for Publishing Cutting-Edge Research Discoveries in Medicine, Biology and Chemistry.”. Discoveries (Craiova, Romania) 1 (1): e1.
Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment.
Duquette, Mark, Peter M Sadow, Jack Lawler, and Carmelo Nucera. 2013. “Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells With BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment.”. Frontiers in Endocrinology 4: 189.
FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma.
Bellelli, Roberto, Maria Domenica Castellone, Ginesa Garcia-Rostan, Clara Ugolini, Carmelo Nucera, Peter M Sadow, Tito Claudio Nappi, et al. 2012. “FOXM1 Is a Molecular Determinant of the Mitogenic and Invasive Phenotype of Anaplastic Thyroid Carcinoma.”. Endocrine-Related Cancer 19 (5): 695-710.
Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer?
Nucera, Carmelo, and Alfredo Pontecorvi. 2012. “Clinical Outcome, Role of BRAF(V600E), and Molecular Pathways in Papillary Thyroid Microcarcinoma: Is It an Indolent Cancer or an Early Stage of Papillary Thyroid Cancer?”. Frontiers in Endocrinology 3: 33.
Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.
Nehs, Matthew A, Carmelo Nucera, Sushruta S Nagarkatti, Peter M Sadow, Dieter Morales-Garcia, Richard A Hodin, and Sareh Parangi. 2012. “Late Intervention With Anti-BRAF(V600E) Therapy Induces Tumor Regression in an Orthotopic Mouse Model of Human Anaplastic Thyroid Cancer.”. Endocrinology 153 (2): 985-94.
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.
Nucera, Carmelo, Jack Lawler, and Sareh Parangi. 2011. “BRAF(V600E) and Microenvironment in Thyroid Cancer: A Functional Link to Drive Cancer Progression.”. Cancer Research 71 (7): 2417-22.
Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer.
Nehs, Matthew A, Sushruta Nagarkatti, Carmelo Nucera, Richard A Hodin, and Sareh Parangi. 2010. “Thyroidectomy With Neoadjuvant PLX4720 Extends Survival and Decreases Tumor Burden in an Orthotopic Mouse Model of Anaplastic Thyroid Cancer.”. Surgery 148 (6): 1154-62; discussion 1162.